medigraphic.com

2013, Number 1

<< Back Next >>

Rev Esp Cienc Salud 2013; 16 (1)

Adverse effect of extended release anorexiants drugs

Espinosa-Franco B, Morín-Zaragoza R

Language: Spanish
References: 20
Page: 32-40
PDF size: 636.89 Kb.


ABSTRACT

There are few data available of the benefits and the risks of prolonged therapies with anorexiants in Mexico. The objective of this study was to determine the adverse effects and severity that the consulted physician observed in patients to whom they prescribed with any on the following anorexiants of extended release: d-norpseudoephedrine hydrochloride, phentermine, amfepramone, fenproporex, mazindol and clobenzorex hydrochloride, except sibutramine. The results obtained in different states of Mexican Republic were compared with reports from the United State of America and the Europe. A transversal, prolective, observational and descriptive study was made, along with a structured questionnaire which inquired about the adverse effects commonly reported in the literature, and the severity of the reaction ranging from mild, moderate and severe. The questionnaire was applied to 555 physicians attending the pharmacological treatment of obesity course, during 2007 and 2008 in Hidalgo, San Luis Potosi, Mexicali, Estado de Mexico and North, South, East and West of Mexico City. The highest frequency of the adverse effect reported was for sibutramine and the lowest frequencies were for phentermine and amfepramone. When using sibutramine, an increase of blood pressure, tachycardia and palpitations were found.


REFERENCES

  1. OMS. Obesidad y sobrepeso. Nota descriptiva No. 311; Mayo 2012. Disponible en: URL. http://www.who.int/mediacentre/factsheets/ fs311/es/index.html

  2. Encuesta Nacional de Salud y Nutrición 2006. La salud de los adultos. Cuernavaca, Morelos, México. Instituto Nacional de Salud Pública.

  3. Kolanowski J. Risk-benefit assessment of anti-obesity drugs. Drug Safety 1999; 20(2): 119-131.

  4. Ioannides-Demos L, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drug 2005; 65(10): 1391-1418.

  5. Ioannides-Demos L, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Safety 2006; 29(4);277-302.

  6. NORMA Oficial Mexicana NOM-220-SSA1-2012, Instalación y operación de la farmacovigilancia. Diario Oficial. 07 de enero 2013.

  7. Kinnell HG. European withdrawal of appetite suppressants. Obesity reviews 2003; 4: 79-81.

  8. Manson JE, Faich GA. Pharmacotherapy For obesity-do the benefits outweigh the risks? N Engl J Med 1996; 335(9): 659-660

  9. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC. Metaanalysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.

  10. Weiser M, Frishman WH, Michaelson MD, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997; 37: 453-473.

  11. Dunham DB, Savaske SA. Obesity: an update. Pharmacotherapy J Pharmacy Society of Wisconsin Nov/Dec. 1999; 17-23.

  12. Wasan KM, Looige NA. Emerging pharmacological approaches to the treatment of obesity. J Pharm Pharmaceut Sci 2005; 8(2): 259-271.

  13. Bastarrachea RA, Laviada-Molina H, Henández-Esclante V, Tejero E, Montero JC, Comuzzie AG. Medicina basada en evidencias en el desarrollo de fármacos antiobesidad: conceptos actuales y perspectivas futuras. Available from: URL: http:// www.saota.org.ar/F.

  14. Lean M, Mullan A. Obesity: wich drug and when? Int J Clin Pract 2007; 61(9): 1555-1560.

  15. Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrin Metabolism 2003; 88(6): 2462-2469.

  16. Salem V, Bloom SR. Approaches to the pharmacological treatment of obesity. Expert Rev Clin Pharmacol 2010; 3(1): 73-88.

  17. Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab 2006; 50(2): 1-20.

  18. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). 10 de agosto de 2010. Available from: URL: http://www.fda.gov/drugs/drugsafety/ucm228746.htm

  19. COFEPRIS, Gobierno Federal,COFEPRIS ratifica ante laboratorios la orden de retirar la sibutramina. 14 de octubre de 2010. Available from: URL: http://www.cofepris.go.mx

  20. Morín ZR, Lonngi G, Alcaraz OR, Rosas HD. Comparación de dos formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratado durante seis meses. Med Int Mex 2001; 17 (6) : 260-271.




2020     |     www.medigraphic.com